Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn:
“Genomic testing is already helping some women with early breast cancer avoid chemotherapy.
What makes the OPTIMA trial, presented at ASCO 2026, so important is that it studied patients traditionally considered at higher risk—including premenopausal women and patients with multiple positive lymph nodes.
About two-thirds of patients had a low Prosigna (PAM50) Risk of Recurrence score and were able to follow a treatment strategy that reduced the use of chemotherapy without compromising outcomes.
OPTIMA is one of the largest studies to evaluate whether a genomic test can guide chemotherapy decisions in higher-risk hormone receptor-positive, HER2-negative breast cancer.
I recently interviewed Professor Andreas Makris, co-chair of the OPTIMA trial, to discuss the study results and what they could mean for patients and clinicians.
Could genomic testing help even more women safely avoid chemotherapy in the future?”
More posts featuring Francisco J. Esteva.